> ## Content Index
> Fetch the complete content index at: https://www.healthdatacon.io/llms.txt
> Use this file to discover other available public pages before exploring further.

# Brian Levine puts the IVF laboratory at the center of fertility’s access problem
- URL: https://www.healthdatacon.io/articles/brian-levine-ivf-laboratory-fertility-access-hlth-2026/
- Published: 2026-11-17T18:40:00.000Z
- Updated: 2026-11-19T04:06:31.000Z
- Description: Brian Levine sees automation easing an embryology bottleneck, while warning that promising fertility science still has to reach people who cannot afford care.
- Author: HDM Staff
- Tags: Patient Care, Americas, HLTH

Fertility care will not reach more Americans simply by training more doctors, reproductive endocrinologist Brian Levine said. The harder constraint, in his account, sits inside the laboratory: the specialized workers who prepare eggs, handle sperm and grow embryos, and whose capacity limits how many patients a clinic can treat.

Levine, founding physician and practice director at CCRM Fertility of New York and founder of surrogacy platform Nodal, made that distinction while discussing the future of reproductive medicine with Christina Farr. The Second Opinion CEO and editor-in-chief moderated their November 17 [Revv Stage conversation](https://hlth.com/events/usa/agenda/2026/the-future-of-baby-making?ref=healthdatacon.io) at HLTH USA 2026 in Las Vegas. His argument connected the mechanics of IVF with the distances patients travel, the price of treatment and the question of who benefits from the next generation of fertility technology.

“The biggest bottleneck that we have are embryologists,” Levine said. He welcomed a wider role for obstetrician-gynecologists and advanced practice professionals, but argued that adding clinical appointments would not by itself expand the laboratory work needed to turn those appointments into treatment. Making embryology a more visible career and reducing repetitive work were both part of his proposed response.

## The laboratory determines what a clinic can deliver

Levine described an access problem that starts before patients reach a laboratory. Fertility specialists cluster near the coasts, he said, leaving some patients traveling hundreds of miles for monitoring visits during treatment. He also said clinics underserve Black and brown communities and people who do not speak English, even as they develop services for patients already able to pay and travel.

That distinction matters to his assessment of innovation. A laboratory improvement can increase the reliability or capacity of a clinic, but patients still need an accessible provider, understandable information and a way to finance treatment. Levine’s definition of progress was practical: “The future of baby making, in my mind, is doing it faster, cheaper, and better.” He presented those goals together rather than treating a sophisticated procedure as sufficient evidence that access had improved.

Inside the laboratory, he separated skilled judgment from preparation tasks that consume an embryologist’s time. Preparing dishes and handling materials must be done correctly, but repeating those tasks does not necessarily require the same human involvement as making consequential decisions about reproductive cells. Levine saw room for robotics to take on routine work while trained staff continued to oversee the process.

He pointed particularly to intracytoplasmic sperm injection, or ICSI, in which one sperm is injected into an egg. Positioning the egg, selecting sperm and manipulating the injection needle demand precision, he said. Standardizing those steps could reduce variation between operators, although a plausible engineering rationale does not establish better birth outcomes.

## Automation has evidence and limits

Farr disclosed during the discussion that she is an investor in Conceivable Life Sciences, a company working on IVF laboratory automation. That financial interest is relevant to her questions about the technology. Levine’s response emphasized an enduring need for embryologists alongside machines, with automation potentially changing the tasks they spend time performing.

A company-hosted [proof-of-concept paper](https://www.conceivable.life/research-papers/automate-oocyte-retrieval?ref=healthdatacon.io) provides a narrower picture than a fully autonomous laboratory. It describes 11 patients treated with at least two prototype automated systems in sequence, with five live births. Human operators remained involved, and the authors identified speed, training and scalability limitations. The small pilot supports feasibility; it does not establish that automation improves cumulative birth rates or reduces the price patients ultimately pay.

Levine’s focus on the laboratory is consistent with the importance of measuring actual clinical results. The CDC’s [reporting guidance](https://www.cdc.gov/art/success-rates/interpret.html?ref=healthdatacon.io) cautions that fertility-clinic success rates vary with patient characteristics, treatment methods and laboratory expertise. Comparing a machine with manual work therefore requires attention to who was treated and what outcomes were measured, not simply how many steps a device can perform.

## A shorter treatment cycle is still an investigational promise

Levine also highlighted approaches that could reduce the burden of ovarian stimulation before eggs are retrieved. His strongest example concerned patients facing urgent cancer treatment, for whom the time available to preserve fertility can be limited. A shorter process could matter to them differently than it would to someone arranging treatment around work.

The corporate development behind that discussion needs a precise distinction. Ferring and Gameto [announced an agreement](https://www.gametogen.com/news/ferring-pharmaceuticals-and-gameto-sign-agreement-for-proposed-acquisition/?ref=healthdatacon.io) on October 27 for a proposed acquisition valued at up to $1.3825 billion, subject to milestones and closing conditions. Their announcement said Gameto’s in vitro maturation program remained investigational in the United States and lacked FDA approval. Levine’s enthusiasm for a shorter treatment course should therefore be understood as a discussion of an emerging approach, not a statement that it is routinely available to U.S. patients.

His account of growing demand for egg freezing also raised a counseling question. He described patients arriving with the conviction that they needed the procedure because their peers had undergone it, rather than after considering their own circumstances. The American Society for Reproductive Medicine’s [ethics opinion](https://integration.asrm.org/practice-guidance/ethics-opinions/planned-oocyte-cryopreservation/?ref=healthdatacon.io) calls for disclosure of costs, risks, uncertainties and clinic-specific outcomes. It also identifies ASRM’s removal of the experimental label in 2012, rather than an FDA decision making egg freezing commercially available.

## Surrogacy exposes the affordability test

The conversation returned to costs when Farr asked about Nodal. Levine said its technology seeks to make matching and screening for gestational surrogacy more efficient and to reduce the role of intermediaries. He put a typical U.S. surrogacy journey at roughly $250,000 and said Nodal could bring it closer to $125,000\. Those were his estimates, offered as the company’s founder; the session did not provide a comparable independent accounting of costs or outcomes.

Even his lower figure illustrates the scale of the affordability problem. Reducing an expensive process substantially can still leave it beyond the reach of many families. For employers considering reproductive benefits and clinics considering new technology, the relevant question is whether a change expands treatment for people previously excluded, alongside whatever operational improvement it delivers.

Levine’s more distant forecasts included artificial wombs and eggs or sperm derived from other cells. He distinguished the possibility of developing technology from the much longer process of establishing outcomes and gaining acceptance. The FDA’s [artificial-womb review](https://www.fda.gov/advisory-committees/advisory-committee-calendar/pediatric-advisory-committee-meeting-announcement-09192023?ref=healthdatacon.io), for example, has focused on support for extremely premature infants, a different use from replacing an entire pregnancy. His timeline predictions were forecasts, not evidence of an available clinical option.

The immediate challenge in his remarks remained closer to the clinic floor. Reliable laboratory work, enough trained people, lower burdens on patients and a workable route into care all have to advance together. “Everyone who wants to have a child deserves to have a child,” Levine said. Turning that aspiration into broader access will require evidence that innovations change who can obtain treatment, as well as how treatment is performed.